{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '13', 'STUDY MONITORING', '13.1 RESPONSIBILITIES OF THE INVESTIGATOR(S)', 'The Investigator is required to ensure compliance with all procedures required by the clinical trial', 'protocol and with all study procedures provided by the Sponsor (including security rules). The', 'Investigator agrees to provide reliable data and all information requested by the clinical trial', 'protocol (with the help of the CRF, Discrepancy Resolution Form [DRF] or other appropriate', 'instrument) in an accurate and legible manner according to the instructions provided and to ensure', 'direct access to source documents by Sponsor representatives.', 'If any circuit includes transfer of data particular attention should be paid to the confidentiality of', \"the patient's data to be transferred.\", 'The Investigator may appoint such other individuals as he/she may deem appropriate as', 'Sub-investigators to assist in the conduct of the clinical trial in accordance with the clinical trial', 'protocol. All Sub-investigators shall be appointed and listed in a timely manner. The', 'Sub-investigators will be supervised by and work under the responsibility of the Investigator. The', 'Investigator will provide them with a copy of the clinical trial protocol and all necessary', 'information.', '13.2 RESPONSIBILITIES OF THE SPONSOR', 'The Sponsor of this clinical trial is responsible to regulatory authorities for taking all reasonable', 'steps to ensure the proper conduct of the clinical trial as regards ethics, clinical trial protocol', 'compliance, and integrity and validity of the data recorded on the e-CRFs. Thus, the main duty of', 'the monitoring team is to help the Investigator and the Sponsor maintain a high level of ethical,', 'scientific, technical and regulatory quality in all aspects of the clinical trial.', 'At regular intervals during the clinical trial, the site will be contacted, through monitoring visits,', 'letters or telephone calls, by a representative of the monitoring team to review study progress,', 'Investigator and patient compliance with clinical trial protocol requirements and any emergent', 'problems. These monitoring visits will include but not be limited to review of the following', 'aspects: patient informed consent, patient recruitment and follow-up, SAE documentation and', 'reporting, AESI documentation and reporting, AE documentation, IMP allocation, patient', 'compliance with the IMP regimen, IMP accountability, concomitant therapy use and quality of', 'data.', '13.3 SOURCE DOCUMENT REQUIREMENTS', 'According to the ICH GCP, the monitoring team must check the e-CRF entries against the source', 'documents, except for the pre-identified source data directly recorded in the e-CRF. The ICF will', \"include a statement by which the patient allows the Sponsor's duly authorized personnel, the\", 'ethics committee (IRB/IEC), and the regulatory authorities to have direct access to original', \"medical records which support the data on the e-CRFs (eg, patient's medical file, appointment\", 'Property of the Sanofi Group - strictly confidential', 'Page 126', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'books, original laboratory records). These personnel, bound by professional secrecy, must', 'maintain the confidentiality of all personal identity or personal medical information (according to', 'confidentiality and personal data protection rules).', '13.4 USE AND COMPLETION OF CASE REPORT FORMS (CRFS) AND ADDITIONAL', 'REQUEST', 'It is the responsibility of the Investigator to maintain adequate and accurate e-CRFs (according to', 'the technology used) designed by the Sponsor to record (according to Sponsor instructions) all', 'observations and other data pertinent to the clinical investigation in a timely manner. All e-CRFs', 'should be completed in their entirety to ensure accurate interpretation of data.', 'Should a correction be made, the corrected information will be entered in the e-CRF overwriting', 'the initial information. An audit trail allows identifying the modification.', 'Data are available within the system to the Sponsor as soon as they are entered in the e-CRF.', 'The computerized handling of the data by the Sponsor may generate additional requests (DRF) to', 'which the Investigator is obliged to respond by confirming or modifying the data questioned. The', 'requests with their responses will be managed through the e-CRF.', '13.5 USE OF COMPUTERIZED SYSTEMS', 'The complete list of computerized systems used for the study is provided in a separate document', 'which is maintained in the Sponsor and Investigator study files.', 'Property of the Sanofi Group - strictly confidential', 'Page 127', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}